| eseba-vec (HB-200) / Hookipa Pharma |
H-200-004, NCT06513884: A Phase 2/3 Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer |
|
|
| Not yet recruiting | 2/3 | 450 | NA | HB-202/HB-201 alternating 2-vector therapy, HB-202 intravenous administration alternating with HB-201 intravenous administration, HB-201 & HB-202 two-vector therapy, TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV16+) Specific Antigens, Placebo, Matched placebo, Pembrolizumab, Keytruda® | Hookipa Biotech GmbH | Oropharyngeal Squamous Cell Carcinoma Recurrent | 11/29 | 04/32 | | |
NCT06373380: A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC) |
|
|
| Recruiting | 2 | 51 | US | HB-200, Placebo | Memorial Sloan Kettering Cancer Center, Hookipa Biotech GmbH, Naveris | HPV16+ Squamous Cell Carcinoma | 04/27 | 04/27 | | |
2019-000907-34: A clinical trial to test the regimen of two cancer treatment vaccines in patients with human papillomavirus 16 confirmed cancers. Un ensayo clínico para comprobar el régimen de dos vacunas para el tratamiento del cáncer en pacientes con cánceres de virus papiloma humano 16 confirmados |
|
|
| Not yet recruiting | 1/2 | 200 | Europe | HB -201, HB-202, Solution for injection/infusion, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, KEYTRUDA 25 mg/ml concentrate for solution for infusion, KEYTRUDA 50 mg Powder for concentrate for solution for infusion | Hookipa Biotech GmbH, Hookipa Biotech | Human papilloma virus (HPV 16) associated cancer Cáncer asociado a virus papiloma humano (VPH 16), Diseases [C] - Cancer [C04] | | | | |
| Recruiting | 1/2 | 200 | Europe, US | HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C) | Hookipa Biotech GmbH, Hookipa Biotech | HPV-Related Squamous Cell Carcinoma | 06/25 | 06/26 | | |
| Recruiting | 1/2 | 98 | US | HB-201, TheraT® Vectors, HB-202, Carboplatin, Paclitaxel, Transoral Robotic Surgery, TORS | University of Chicago | Human Papilloma Virus, HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer | 01/26 | 01/26 | | |
